德國欣髮源 Thymuskin

我們在 Darmstadt皮膚科診所（Darmstadt Dermatology Clinic ）對36名患者進行兩項研究 。 第一項研究是測試 德國欣髮源 Thymuskin 對16位至少患有圓禿（AA）12個月的以上的患者進行效果測試。

•8 名女性（平均年齡42.3 歲，平均病史期間65.5 個月）

•8 男性（平均年齡30.8 歲，平均病史期間34.5 個月）

患者為有超過五個落髮區或受匍行性落髮所苦。一半的患者曾接受一個或多個初步治療，但只有兩位患者身上看見短暫的成功。

患者先使用 德國欣髮源 Thymuskin 洗髮精與凝膠為期12 個月；洗髮精頭兩個禮拜每天用，接著每週三次。凝膠則頭兩個星期每週使用兩次，然後每天早晨一次。此實驗採用醫生與病人的主觀評價，以及客觀參數（每天掉髮量），患者在治療過程中體驗到每天落髮量減少，且多數患者出現重新生髮。

1.減少落髮

在療程結束時，每天掉髮量由245 根減為10 根（96%的減少）

12 個月治療期的掉髮量變化

2.毛髮的新生

•86％的患者在治療結束時，顯示新髮生長上的進步

不同治療長度與相對的症狀改善

在另一項由Darmstadt 皮膚科診所（Darmstadt Dermatology Clinic ）進行的研究裡，我們對20 位（14 名女性和6 名男性，其中包括2 名兒童）患有全頭禿或全身禿的患者，進行 德國欣髮源 Thymuskin 為期9-24 個月的療程。

•5 名斑禿患者（平均病史時間66 個月）

•15 名全禿患者（平均病史時間44.7 月）

大多數患者曾試過下列療法但失敗，包含類固醇，二苯基环丙烯酮（DPCP），4 - [（4-氨基苯）磺酰基]苯胺（氨苯砜）或光化學療法。研究中的患者頭兩星期每天使用 德國欣髮源 Thymuskin 洗髮精，然後每週使用二到三次 。並在頭兩個星期，每日使用養護精華凝膠，接著每天使用一次。大約9-24 個月過後，65％的患者表現出新髮生長，有40％的患者症狀被緩解。相比之下，用DPCP 治療通常僅有21到28％的患者的症狀能夠得到緩解。

3.症狀完全或部分被緩解

•40％患者症狀完全被緩解：頭皮區域的毛髮完全生長（6/20）或全身毛髮的生長（2/20）

•25%患者部分症狀被緩解：良好的毛髮生長狀況（2/20）或頭部和身體的毛髮適度增長（3/20）

臨床實驗發現（20 名患有全頭禿或全身禿案例）

經過一年 德國欣髮源 Thymuskin 的治療，40歲的全頭禿患者症狀獲得大幅改善

德國欣髮源 THYMUSKIN 對全頭禿患者的效果測試

»每日掉髮量降低96％

»65％-86％的患者顯示有新髮生長

» 40％的患者症狀獲得大幅改善

原文：

Alopecia areata

Two studies were performed at the Darmstadt Dermatology Clinic9,10 on a total of 36 patients.

The first study at the Darmstadt Dermatology Clinic9 investigated Thymuskin’s effectiveness in 16 patients with alopecia areata (AA) over a period of 12 months:

• 8 women (average age 42.3, average medical history duration 65.5 months)

• 8 men (average age 30.8, average medical history duration 34.5 months)

The patients exhibited either more than five hairless areas or were suffering from ophiasis-typealopecia. Half of the patients had previously undergone one or more preliminary treatments, which offered fleeting success in only two patients.

The patients used Thymuskin shampoo and scalp serum for a period of 12 months: hair shampoo daily for the first two weeks then three times a week, serum twice daily in the first two weeks then once a day in the morning. The success of the treatment was evaluated using subjective assessments by the doctor and patient as well as objective parameters (quantity of hairs falling out per day). The patients experienced a reduction in daily hair loss during the treatment, and the majority of patients experienced renewed hair growth.

1. Reduction in hair loss9

• The average number of hairs falling out per day decreased from 245 to 10 by the

end of the treatment (a reduction of 96%)

2. New hair growth9

• 86% of patients demonstrated a subjective improvement in results (new hair

growth) at the end of the treatment

In another study by the Darmstadt Dermatology Clinic10, 20 patients (14 women and 6 men, including 2 children) with A. areata totalis or A. areata universalis used Thymuskin for a period of 9-24 months.

• 5 patients with A. areata totalis (average medical history duration 66 months)

• 15 patients with A. areata universalis (average medical history duration 44.7

months)

Most patients had previously undergone unsuccessful treatment with steroids, diphenylcyclopropenone (DPCP), 4-[(4-aminobenzene)sulfonyl]aniline (dapsone) or PUVA. The patients in the study used Thymuskin Shampoo daily for the first two weeks and then two or three times a week. The scalp serum was used twice daily in the first two weeks and then once a day. After 9-24 months, 65% of patients exhibited new hair growth and 40% of patients were in full remission.

In comparison, treatment with DPCP usually results in full remission being observed in approx. 21-28% of patients.

3. Full and partial remission10

• Full remission in 40% of patients: complete growth in scalp region (6/20) or full body hair growth (2/20)

• Partial remission in 25% of patients: excellent hair growth (2/20) or moderate growth of head and body hairs (3/20)

Clinical findings in 20 patients with alopecia totalis or universalis

Thymuski n® effectiveness in patients with alopecia areata

»» Number of hairs lost daily reduced by 96%9

»» New hair growth in 65%10-86%9 of patients

»» Full remission in 40% of patients10